Randomized trial demonstrates improved overall survival with cetuximab added to platinum-fluorouracil in recurrent or metastatic head and neck cancer, supporting its first-line use.
As compared with platinum-based chemotherapy plus fluorouracil alone, cetuximab plus platinum-fluorouracil chemotherapy improved overall survival when given as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck. (ClinicalTrials.gov number, NCT00122460.)
No takes yet. Share an insight, caveat, or question.
Vermorken et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: